Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome (CSPC Pharmaceutical Group, 6753b2)
- Development stage
- Unknown
- Lead developer
- CSPC ZhongQi Pharmaceutical Technology
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Mitoxantrone Hydrochloride Liposome (PLM60) is a PEG-modified liposomal formulation of mitoxantrone, a synthetic anthracenedione antineoplastic agent. Developed by CSPC ZhongQi Pharmaceutical Technology, this formulation utilizes 60 nm vesicles to optimize pharmacokinetics, increasing drug concentration within tumor tissues while minimizing exposure to healthy organs such as the heart and kidneys. The drug functions by intercalating into DNA and inhibiting topoisomerase II, which leads to DNA strand breaks and the inhibition of nucleic acid synthesis. It is currently approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and is being evaluated in clinical trials for other forms of Non-Hodgkin's lymphoma.
- Brand names
- Duoenda
- Other names
- Mitoxantrone Hydrochloride Liposome InjectionPEGylated Mitoxantrone Hydrochloride Liposome
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on Mitoxantrone Hydrochloride Liposome (CSPC Pharmaceutical Group, 6753b2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitoxantrone Hydrochloride Liposome (CSPC Pharmaceutical Group, 6753b2).